Dr. Ann Mazor Reed, DO

Dr. Reed practices at Dermatology Group of Florida, P.A. in South Miami, Florida.

Dr. Reed's NPI, 1669717773, was assigned on November 29, 2012. Dr. Reed graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 2012. Dr. Reed holds Florida license OS12286.

Dr. Reed's primary practice is Dermatology Group of Florida, P.A., at 7800 Sw 57th Ave, South Miami, FL 33143 in Miami-Dade County. The practice phone is (954) 807-9332.

Dr. Reed's primary practice is Dermatology Group of Florida, P.A. in South Miami, Florida. The medical group on file is Dermatology Group of Florida. Dmand AI also links Dr. Reed to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reed practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Reed's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Reed is board certified in dermatology by the AOA Board of Dermatology. Dr. Reed is licensed in Florida.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, corns and calluses, facial skin infection and hives among the conditions Dr. Reed treats.

CMS data shows 8,038 Medicare services from Dr. Reed across 26 procedure codes in 2024, for 1,442 Medicare patients. Medicare paid $387,293 for them. Every service was in an office.

CMS counts 1,442 Medicare patients who saw Dr. Reed in 2024. The largest group is 65 to 74, with 685 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Reed's median patient age at 60, with 62% women.

In 2024, Dr. Reed wrote 604 Medicare Part D claims for 269 patients. 91% of them were for generic drugs. CMS names the drug for 503 of them, across 14 drugs with 11 or more claims each, at $63,350 in total drug cost. In 2023, CMS named 475 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Reed for performance year 2024, reported individually. Dr. Reed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,305 procedures of removal of skin lesions by Dr. Reed, more than 98% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Reed in 2025. Dr. Reed's most frequent co-authors are Sunil S. Dhawan, MD, Justin Meng Ko, MD and Arash Mostaghimi, MD, MPA, MPH.

Dmand AI links Dr. Reed to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Alopecia, Eczema and Dermatitis, Atopic. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Reed that name 2 trials.

CMS Open Payments shows 877 general payments to Dr. Reed from 41 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 64% of the total. Pfizer Inc. paid the most, $54,474. It also lists 3 research payments totaling $15,199 in 2023, naming 2 clinical trials.

Dr. Reed graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 2012.

Dr. Reed is in network with 18 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.